AI Science Tracker
EN

A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes

Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, United States. · 19 Jul 2023 · medicine

Discovery

A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: RF selection of an exosome protein signature from published proteomic datasets and evaluation across cancer/normal datasets; linked bioRxiv preprint carries the same result. The result is limited to the reported study population and evaluation; the source does not establish transfer to other populations or improved clinical outcomes.

Technology: Random-forest selection of an exosome-protein signature

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Random-forest selection of an exosome-protein signature
Limitation / still unknown
The study does not establish improved patient outcomes or generalization beyond the evaluated setting.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://elifesciences.org/articles/90390.pdf · https://doi.org/10.7554/elife.90390 · https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38529947&retmode=xml

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.